Stig Müller

• Hannestad, Ingrid; Myklebust, Tor Åge; Fosså, Sophie Dorothea; Müller, Stig & Aas, Kirsti (2026). Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment? World Journal of Urology. ISSN 0724-4983. 44(1). doi: 10.1007/s00345-026-06617-5. Fulltekst i vitenarkiv Vis sammendrag

  Purpose Active surveillance (AS) is an established management strategy for men with low- and favorable intermediate-risk prostate cancer (PCa). Nevertheless, a substantial proportion of patients ultimately undergo radical prostatectomy (RP), and the impact of prior AS on subsequent outcomes remains uncertain. We therefore compared surgical methods, adverse pathological findings and post-RP PCa-treatment among men undergoing deferred RP after AS with those of comparable men treated with immediate RP. Methods Using nationwide data from the Norwegian Prostate Cancer Registry, we identified men diagnosed between 2009 and 2022 with low- or intermediate-risk PCa who underwent deferred RP following AS or immediate RP. Descriptive statis tics summarized clinical characteristics and surgical methods. Multivariable logistic regression evaluated adverse pathologi cal findings in the surgical specimen, and Cox proportional hazards models analyzed post-RP PCa-treatment. Kaplan-Meier analyses with log-rank test assessed 10-year PCa-specific survival. Results Compared with immediate RP (n = 5767), the deferred RP (n = 1839) group had more unfavorable preoperative tumor characteristics, fewer nerve-sparing procedures and more frequent lymph node dissection. Deferred RP after AS was associated with higher risk of adverse pathological findings (OR 1.99, 95% CI 1.8–2.3) and post-RP PCa-treatment (HR 1.52, 95% CI 1.3–1.8). Ten-year PCa-specific survival did not differ between groups. Limitations include incomplete data on surveillance intensity. Conclusion Deferred RP after AS was associated with more extensive surgery, adverse pathological findings and post-RP PCa-treatment, but similar ten-year PCa-specific survival, compared to immediate RP. These findings emphasize the need for surveillance strategies that ensure timely detection of disease progression and transition to radical treatment.

• Ferreira, Nádia Gonçalves; Thomas, Owen Matthew Truscott; Gjesdal, Kjell Inge; Müller, Stig; Oldenburg, Jan & Syversen, Ingrid Framås [Vis alle 8 forfattere av denne artikkelen] (2026). Artificial intelligence in prostate MRI: Comparative diagnostic performance in a high-prevalence cohort. Acta Radiologica. ISSN 0284-1851. doi: 10.1177/02841851261470455. Fulltekst i vitenarkiv
• Breen, Bendik Stensby; Alghofaily, Khalefa; Christensen, Heidi Søgaard; Frøkjær, Jens Brøndum; Graumann, Ole & Kleivane, Mats [Vis alle 14 forfattere av denne artikkelen] (2026). Agreement of axial T2-MRI versus Contrast-Enhanced CT for solid renal mass active surveillance. Abdominal Radiology. ISSN 2366-004X. doi: 10.1007/s00261-026-05376-6. Fulltekst i vitenarkiv
• Borgbjerg, Jens; Breen, Bendik Stensby; Kristiansen, Cathrine Helgestad; Larsen, Nis Elbrønd; Medrud, Lise & Mikalone, Rasa [Vis alle 12 forfattere av denne artikkelen] (2025). Agreement between Routine-Dose and Lower-Dose CT with and without Deep Learning–based Denoising for Active Surveillance of Solid Small Renal Masses: A Multiobserver Study. Radiology: Imaging Cancer. 7(4). doi: 10.1148/rycan.240250. Fulltekst i vitenarkiv Vis sammendrag

  Interobserver agreement for CT-based assessment of small renal masses during active surveillance was similar between routine-dose and lower-dose images acquired using iterative reconstruction, and deep learning–based denoising enabled dose reduction to submillisievert levels.

• Hannestad, Ingrid; Myklebust, Tor Åge; Fosså, Sophie Dorothea; Müller, Stig & Aas, Kirsti (2025). Real-world implementation and guideline adherence at inclusion of active surveillance for men with prostate cancer: a population-based study from the Cancer Registry of Norway. Scandinavian Journal of Urology. ISSN 2168-1805. 60, s. 218–225. doi: 10.2340/sju.v60.45023. Fulltekst i vitenarkiv Vis sammendrag

  Objectives: This study aimed to evaluate the implementation of and adherence to national guidelines at inclusion amongst men with newly diagnosed prostate cancer (PCa) managed with active surveillance (AS) in Norway. Materials and methods: We conducted a population-based cohort study using data from the Norwegian Prostate Cancer Registry, encompassing all men diagnosed with PCa and managed with AS from 2009 to 2022. We assessed guideline adherence based on AS inclusion criteria defined in the national guidelines and analysed the factors associated with adherence. Non-adherence was defined as inclusion in AS despite not meeting formal criteria. Results: Among 69,996 men diagnosed with PCa, 11 449 (16.4%) were managed with AS. Overall adherence to national guidelines for AS inclusion was 64%, rising from 60% in 2009 to 77% in 2022, with a notable increase after the 2020 guideline update. Higher adherence was associated with more recent diagnoses, younger age, lower Eastern Cooperative Oncology Group (ECOG) performance status, and evaluation by a private specialist. Significant regional variations in guidelines adherence were observed. Conclusions: While the use of AS for localised PCa increased in Norway over time, only two in three men were eligible for AS and regional variations persisted. This study highlights the need for strategies to standardise AS implementation across healthcare settings to ensure uniform and evidence-based management of patients with localised PCa nationwide.

• Kjøbli, Eirik; Haug, Erik Skaaheim; Salvesen, Øyvind Olav; Arstad, Christian; Bergesen, Anne Kvåle & Brennhovd, Bjørn [Vis alle 23 forfattere av denne artikkelen] (2025). “Modernized” en Bloc Radical Cystectomy Versus Standard Radical Cystectomy: A Nationwide Multi-Institutional Propensity Score Matched Analysis. Cancers. 17(3). doi: 10.3390/cancers17030404. Fulltekst i vitenarkiv Vis sammendrag

  Background: Pelvic lymph node dissection during standard radical cystectomy (stdRC) for muscle invasive bladder cancer is performed as separate templates. In the modernized en bloc radical cystectomy (mEbRC), the bladder is removed together with all its associated lymphatic tissue as one specimen. Our aim was to evaluate the oncological and surgical outcomes of mEbRC with a propensity-matched national cohort of stdRC cases. Methods: 935 patients (mEbRC: 214 and stdRC: 721) were eligible for analysis, and 1:2 propensity score matching was performed regressing mEbRC treatment on the variables age, gender, neoadjuvant chemotherapy, Charlson Comorbidity Index, lymph node metastases at final pathology, carcinoma in situ, and pT-stage. The primary outcome was recurrence-free survival (RFS). Secondary endpoints were overall survival (OS) and cancer-specific survival (CSS), survival for female patients. and perioperative measures. Results: There were no significant differences between the groups regarding complications, 30-day readmission rates, and 30- and 90-day mortality rates. In the propensity score matched groups, the 5-year RFS was 83% in the mEbRC group vs. 67% in the stdRC group (p < 0.001), the CSS was 89% and 78% (p ≤ 0.001), and OS 81% vs. 68% (p < 0.001) in the same groups, respectively. The results were confirmed by Cox regression analyses with hazard ratios ranging from 0.41 to 0.50 and p-values ≤ 0.001, favoring mEbRC. The 5-year OS for female patients was 86% for mEbRC and 60% for stdRC (p = 0.022). Conclusions: Performing mEbRC over stdRC might yield significantly better oncological outcomes, with equal survival rates for both genders.

• Akhtar, Saima Naz; Gudbrandsdottir, Gigja; Aarsæther, Erling Johan; Carlsen, Birgitte; Dimmen, Magne & Hannestad, Ingrid [Vis alle 14 forfattere av denne artikkelen] (2025). Presentation and survival for urachal cancer: Findings from a nationwide multicenter cohort study in Norway. Urologia. ISSN 0391-5603. 92(4), s. 595–602. doi: 10.1177/03915603251358961. Fulltekst i vitenarkiv Vis sammendrag

  Background and objective: This study aims to map the prevalence and treatment of urachal cancer (UrC) in Norway, establish survival rates, identify prognostic factors, and evaluate whether any of the three commonly used staging systems for UrC provide superior prognostic value. Methods: In this retrospective cohort study, data from the National Cancer Register was collected to identify patients diagnosed with UrC between1997 and2022. Eligible cases (n = 43) underwent retrospective review of their individual hospital records. All patients were staged using the Sheldon, Mayo, and Limonnik-revised TNM systems. This was performed locally and then checked by the coordinating center. Key findings and limitations: The median age at surgery was 59.5 years (IQR 49–73), with 57% of patients being male. The median follow-up time for survivors was 98 months (IQR 81–153). Macroscopic hematuria was the most common presentation (67%, n = 28). Recurrence-free survival (RFS) rates at 1, 3, and 5 years were 71%, 57%, and 53%, respectively. Cancer specific survival (CSS) was 95%, 62%, 55%, and overall survival (OS) rates were 93%, 61%, 46% at the same time points. Smaller tumor size was an independent predictor of improved CSS (HR 1.3, CI: 1.01–1.6, p = 0.045). Of the three staging systems, only the Mayo system showed statistically significant differences between stages for OS, while none of the systems, including Mayo, showed significant differences for CSS. Study limitations include a small sample size and a prolonged study period of 25 years, which may affect the generalizability of the findings and introduce bias due to changes in clinical practice over time, such as advancements in surgical techniques, and oncological therapies. Conclusions and clinical implications: Urachal cancer is frequently diagnosed at an advanced stage. Our findings suggest that the Mayo system more effectively distinguishes between localized, locally advanced, and advanced disease compared to the Sheldon and Limonnik-revised TNM systems.

• Bjerner, Lars; Bratt, Ola; Aas, Kirsti; Albertsen, Peter C.; Fosså, Sophie D. & Kvåle, Rune [Vis alle 16 forfattere av denne artikkelen] (2023). Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. European Urology. ISSN 0302-2838. s. 1–7. doi: 10.1016/j.eururo.2023.04.028. Fulltekst i vitenarkiv Vis sammendrag

  Background Prostate-specific antigen (PSA) levels in midlife are strongly associated with the long-term risk of lethal prostate cancer in cohorts not subject to screening. This is the first study evaluating the association between PSA levels drawn as part of routine medical care in the Norwegian population and prostate cancer incidence and mortality. Objective To determine the association between midlife PSA levels <4.0 ng/ml, drawn as part of routine medical care, and long-term risk of prostate cancer death. Design, setting, and participants The Norwegian Prostate Cancer Consortium collected >8 million PSA results from >1 million Norwegian males ≥40 yr of age. We studied 176 099 men (predefined age strata: 40–54 and 55–69 yr) without a prior prostate cancer diagnosis who had a nonelevated baseline PSA level (<4.0 ng/ml) between January 1, 1995 and December 31, 2005. Intervention Baseline PSA. Outcome measurements and statistical analysis We assessed the 16-yr risk of prostate cancer mortality. We calculated the discrimination (C-index) between predefined PSA strata (<0.5, 0.5–0.9, 1.0–1.9, 2.0–2.9, and 3.0–3.9 ng/ml) and subsequent prostate cancer death. Survival curves were plotted using the Kaplan-Meier method. Results and limitations The median follow-up time of men who did not get prostate cancer was 17.9 yr. Overall, 84% of men had a baseline PSA level of <2.0 ng/ml and 1346 men died from prostate cancer, with 712 deaths (53%) occurring in the 16% of men with the highest baseline PSA of 2.0–3.9 ng/ml. Baseline PSA levels were associated with prostate cancer mortality (C-index 0.72 for both age groups, 40–54 and 55–69 yr). The fact that the reason for any given PSA measurement remains unknown represents a limitation. Conclusions We replicated prior studies that baseline PSA at age 40–69 yr can be used to stratify a man's risk of dying from prostate cancer within the next 15–20 yr. Patient summary A prostate-specific antigen level obtained as part of routine medical care is strongly associated with a man’s risk of dying from prostate cancer in the next two decades. Keywords Prostate cancerScreeningProstate-specific antigen

• Albertsen, Peter C.; Bjerner, Lars Johan; Pasovic, Lara; Müller, Stig; Fosså, Sophie Dorothea & Carlsson, Sigrid V. [Vis alle 7 forfattere av denne artikkelen] (2023). Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge. BJU International. ISSN 1464-4096. 133(1), s. 104–111. doi: 10.1111/bju.16211. Fulltekst i vitenarkiv
• Tahiri, Andliena; Puco, Katarina; Naji, Faris; Kristensen, Vessela N.; Alfsen, G. Cecilie & Farkas, Lorant [Vis alle 10 forfattere av denne artikkelen] (2022). Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors. OncoTarget. 13(1), s. 970–981. doi: 10.18632/oncotarget.28257. Fulltekst i vitenarkiv Vis sammendrag

  Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established biomarkers to predict clinical benefits of a specific TKI. Here, we performed protein tyrosine kinase (PTK) profiling using PamChip® technology. The aim of this study was to identify differences in PTK activity between normal and malignant kidney tissue obtained from the same patient, and to investigate the inhibitory effects of TKIs frequently used in the clinics: sunitinib, pazopanib, cabozantinib and tivozanib. Briefly, our results showed that 36 kinase substrates differs (FDR < 0.05) between normal and cancer kidney tissue, where members of the Src family kinases and the phosphoinositide-3-kinase (PI3K) pathway exhibit high activity in renal cancer. Furthermore, ex vivo treatment of clear cell RCC with TKIs revealed that pathways such as Rap1, Ras and PI3K pathways were strongly inhibited, whereas the neurotrophin pathway had increased activity upon TKI addition. In our assay, tivozanib and cabozantinib exhibited greater inhibitory effects on PTK activity compared to sunitinib and pazopanib, implying they might be better suitable as TKIs for selected RCC patients.

• Müller, Stig; Lilleaasen, Gunder; Sand, Tor-Erik; Løfsgaard, Lars; Estop-Garanto, Manuela & Helgø, Dan [Vis alle 8 forfattere av denne artikkelen] (2018). Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA. World Journal of Urology. ISSN 0724-4983. 36(5), s. 687–691. doi: 10.1007/s00345-018-2252-4. Fulltekst i vitenarkiv
• Aas, Kirsti; Fosså, Sophie Dorothea; Kvåle, Rune; Møller, Bjørn; Myklebust, Tor Åge & Vlatkovic, Ljiljana [Vis alle 8 forfattere av denne artikkelen] (2018). Is time from diagnosis to radical prostatectomy associated with oncological outcomes? World Journal of Urology. ISSN 0724-4983. 37(8), s. 1571–1580. doi: 10.1007/s00345-018-2570-6. Fulltekst i vitenarkiv
• Patel, Hitendra R.H.; Santos, Pedro; Oliveira, Manuel Castanheira de & Müller, Stig (2016). Is robotic-assisted radical cystectomy (RARC) with intracorporeal diversion becoming the new gold standard of care? World Journal of Urology. ISSN 0724-4983. 34(1), s. 25–32. doi: 10.1007/s00345-015-1730-1. Fulltekst i vitenarkiv
• Løvvik, Anja Jacobsen; Müller, Stig & Patel, Hitendra R.H. (2016). Pharmacological Treatment of Post-Prostatectomy Incontinence: What is the Evidence? Drugs & Aging. ISSN 1170-229X. 33(8), s. 535–544. doi: 10.1007/s40266-016-0388-8. Fulltekst i vitenarkiv
• Müller, Stig; Grønning, Leif Erik; Nilsen, Frode S; Mygland, Vegard & Patel, Hitendra R.H. (2014). Robotic and minimal access surgery: Technology and surgical outcomes of radical prostatectomy for prostate cancer. Expert Review of Anticancer Therapy. ISSN 1473-7140. 14(11), s. 1317–1321. doi: 10.1586/14737140.2014.965689. Fulltekst i vitenarkiv
• Nicolaisen, Marianne; Müller, Stig; Patel, Hitendra R.H. & Hanssen, Tove Aminda (2014). Quality of life and satisfaction with information after radical prostatectomy, radical external beam radiotherapy and postoperative radiotherapy: a long-term follow-up study. Journal of Clinical Nursing (JCN). ISSN 0962-1067. 23(23-24), s. 3403–3414. doi: 10.1111/jocn.12586. Fulltekst i vitenarkiv
• Cerantola, Yannick; Valerio, Massimo; Persson, Beata; Jichlinski, Patrice; Ljungqvist, Olle & Hubner, Martin [Vis alle 18 forfattere av denne artikkelen] (2013). Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations. Clinical Nutrition. ISSN 0261-5614. 32(6), s. 879–887. doi: 10.1016/j.clnu.2013.09.014. Fulltekst i vitenarkiv
• Kilminster, Shaun; Müller, Stig; Menon, Mani; Joseph, Jean V.; Ralph, David J. & Patel, Hitendra R.H. (2012). Predicting erectile function outcome in men after radical prostatectomy for prostate cancer. BJU International. ISSN 1464-4096. 110(3), s. 422–426. doi: 10.1111/j.1464-410X.2011.10757.x. Fulltekst i vitenarkiv
• Müller, Stig; How, Ole-Jakob; Jakobsen, Øyvind; Hermansen, Stig Eggen; Røsner, Assami & Stenberg, Thor Allan [Vis alle 7 forfattere av denne artikkelen] (2010). Oxygen-Wasting Effect of Inotropy Is There a Need for a New Evaluation? An Experimental Large-Animal Study Using Dobutamine and Levosimendan. Circulation: Heart Failure. ISSN 1941-3289. 3(2), s. 277–285. doi: 10.1161/CIRCHEARTFAILURE.109.865519. Fulltekst i vitenarkiv
• Rösner, A; Bijnens, B; Hansen, Magna; How, Ole-Jakob; Aarsæther, Erling Johan & Müller, Stig [Vis alle 8 forfattere av denne artikkelen] (2009). Left ventricular size determines tissue Doppler-derived longitudinal strain and strain rate. European Heart Journal-Cardiovascular Imaging. ISSN 2047-2404. 10(2), s. 271–277. doi: 10.1093/ejechocard/jen230. Fulltekst i vitenarkiv
• Hermansen, Stig eggen; Hansen, Magna; Roaldsen, Marius Håke; Müller, Stig; How, Ole-Jakob & Myrmel, truls (2008). Utilization and outcome of coronary revascularization and valve procedures in acute heart failure – an evaluation based on the classification from the European Society of Cardiology. Interactive Cardiovascular and Thoracic Surgery. ISSN 1569-9293. 7, s. 833–838. doi: 10.1510/icvts.2008.175067. Fulltekst i vitenarkiv
• Røsner, Assami; Bijnens, B; Hansen, Magna; How, Ole-Jakob; Aarsæther, Erling Johan & Müller, Stig [Vis alle 8 forfattere av denne artikkelen] (2008). Left ventricular size determines tissue Doppler-derived longitudinal strain and strain rate. European Heart Journal-Cardiovascular Imaging. ISSN 2047-2404. Fulltekst i vitenarkiv
• Hermansen, Stig eggen; Myrmel, truls; Hansen, Magna; How, Ole-Jakob; Müller, Stig & Roaldsen, Marius Håke (2008). How many acute heart failure patients need a ventricular assist device? Scandinavian Cardiovascular Journal. ISSN 1401-7431. 42, s. 118–124. doi: 10.1080/14017430701819113. Fulltekst i vitenarkiv
• Müller, Stig; How, Ole-Jakob; Hermansen, Stig eggen; Stenberg, Thor Allan; Sager, Georg & Myrmel, truls (2008). Vasopressin impairs brain, heart and kidney perfusion: an experimental study in pigs after transient myocardial ischemia. Critical Care. ISSN 1364-8535. 12. doi: 10.1186/cc6794. Fulltekst i vitenarkiv Vis sammendrag

  Introduction: Arginine vasopressin (AVP) is increasingly used to restore mean arterial pressure (MAP) in low-pressure shock states unresponsive to conventional inotropes. This is potentially deleterious since AVP is also known to reduce cardiac output by increasing vascular resistance. The effects of AVP on blood flow to vital organs and cardiac performance in a circulation altered by cardiac ischemia are still not sufficiently clarified. We hypothesised that restoring MAP by low dose, therapeutic level AVP would reduce vital organ blood flow in a setting of experimental acute left ventricular dysfunction. Methods: Cardiac output (CO) and arterial blood flow to the brain, heart, kidney and liver were measured in nine pigs using transit-time flow probes. Left ventricular pressure-volume catheter and central arterial and venous catheters were used for haemodynamic recordings and blood sampling. Transient left ventricular ischemia was induced by intermittent left coronary occlusions resulting in a 17% reduction in cardiac output and a drop in MAP from 87 ± 3 to 67 ± 4 mmHg (p < 0.001). A low-dose therapeutic level of AVP (0.005 U/kg/min) was used to restore MAP to pre-ischemic values (93 ± 4 mmHg). Results: AVP further impaired systemic perfusion (CO and brain, heart and kidney blood flow reduced by 29, 18, 23 and 34%, respectively) due to a 2.0-, 2.2-, 1.9- and 2.1-fold increase in systemic, brain, heart and kidney specific vascular resistances. The hypoperfusion induced by AVP was associated with an increased systemic oxygen extraction. Oxygen saturation in blood drawn from the great cardiac vein fell from 29 ± 1 to 21 ± 3% (p = 0.01). Finally, these effects were reversed 40 min after AVP was withdrawn. Conclusion: Low dose AVP induced a pronounced reduction in vital organ blood flow in pigs after transient cardiac ischemia. This indicates a potentially deleterious effect of AVP in patients with heart failure or cardiogenic shock due to impaired coronary perfusion.

• Jakobsen, Øyvind; Müller, Stig; Aarsæther, Erling Johan; Steensrud, Tor & Sørlie, Dag Glen (2007). Adenosine instead of supranormal potassium in cardioplegic solution improves cardioprotection. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 32(3), s. 493–500. doi: 10.1016/j.ejcts.2007.05.020. Fulltekst i vitenarkiv
• Kjorstad, KE; Kjørstad, Knut Eivind; Nordhaug, dag ole; Korvald, Christian; Muller, S & Müller, Stig [Vis alle 8 forfattere av denne artikkelen] (2007). Mechanical restitution curves - a possible load independent assessment of contractile function. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 31( ), s. 677–684. doi: 10.1016/j.ejcts.2007.01.013. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Borgbjerg, Jens; Kongsrud, Tone; Negård, Anne; Krogh, Nina Rolland; Günther, Thomas & Müller, Stig (2024). CT-veiledet kryoablasjon av nyretumorer. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 144(15). doi: 10.4045/tidsskr.24.0542. Fulltekst i vitenarkiv
• Borgbjerg, Jens; Leland-Try, Marte; Graumann, Ole; Nielsen, Tommy Kjærgaard & Müller, Stig (2024). Accuracy and reproducibility are essential in imaging-based size assessment of renal masses: comment on—"Renal mass imaging modalities: does body mass index (BMI) matter?". International Urology and Nephrology. ISSN 0301-1623. doi: 10.1007/s11255-024-04237-9. Fulltekst i vitenarkiv
• Aas, Kirsti; Fosså, Sophie Dorothea; Kvåle, Rune; Møller, Bjørn; Myklebust, Tor Åge & Vlatkovic, Ljiljana [Vis alle 8 forfattere av denne artikkelen] (2018). Increasing Time from Diagnosis to Radical Prostatectomy (RP-interval) is Not Associated with Adverse Oncological Outcomes: Implications for cancer patient pathways (CPPs). European Urology. Supplement. ISSN 1569-9056. 17(14), s. e2825–e2827. doi: 10.1016/S1569-9056(18)33709-6. Fulltekst i vitenarkiv
• Patel, Hitendra R.H.; Cerantola, Yannick; Valerio, Massimo; Persson, Beata; Jichlinski, Patrice & Ljungqvist, Olle [Vis alle 19 forfattere av denne artikkelen] (2014). Enhanced recovery after surgery: are we ready, and can we afford not to implement these pathways for patients undergoing radical cystectomy? European Urology. ISSN 0302-2838. 65(2), s. 263–266. doi: 10.1016/j.eururo.2013.10.011. Fulltekst i vitenarkiv
• Müller, Stig; Jakobsen, O; How, Ole-Jakob & Myrmel, truls (2007). Levosimendan improves mechanical efficiency in stunned pig hearts. European Journal of Heart Failure. ISSN 1388-9842. 6. Fulltekst i vitenarkiv

Se alle arbeider i NVA